Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

7.090 +0.890 (+14.35%)
Streaming Delayed Price Updated: 1:11 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Friday's session ↗
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Brain and Alcohol Health Pipeline, Receives Phase 2 Trial Approval for FSD202
Via Investor Brand Network
Topics Initial Public Offering
News headline image
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies,... 
Via Newsfile
Topics Initial Public Offering
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Begins First MS Patient Scan in MGH PET Imaging Study
Via Investor Brand Network
News headline image
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 
From Quantum BioPharma
Via GlobeNewswire
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Plans Special Dividend Linked to Litigation Proceeds
Via Investor Brand Network
News headline image
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Clarifies Name, Ownership, and RTO Rumors Involving unbuzzd
Via Investor Brand Network
Topics Initial Public Offering
News headline image
Quantum BioPharma Clarifies It Has Not Changed Its Name
From Quantum BioPharma
Via GlobeNewswire
News headline image
What's Going On With Quantum Biopharma Stock Today? ↗
Quantum Biopharma surges 15% after $2.35M settlement ends legal battle with ex-CEO Raza Bokhari. 
Via Benzinga
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
Via Investor Brand Network
News headline image
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces Auditor Appointment and Name Change for Unbuzzd Wellness
Via Investor Brand Network
Topics Initial Public Offering
News headline image
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
From Quantum BioPharma
Via GlobeNewswire
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients
Via Investor Brand Network
News headline image
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
From Quantum BioPharma
Via GlobeNewswire
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps BitGo to Safeguard Crypto Assets
Via Investor Brand Network
News headline image
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
From Quantum BioPharma
Via GlobeNewswire
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Signs Agreement to Advance MS Drug Toward Phase 2 Trial
Via Investor Brand Network
News headline image
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Stock Pops 20%, Retail Bullish Sentiment Builds After $1M Crypto Holdings Boost ↗
The company increased its Bitcoin and cryptocurrency holdings to $4.5 million, reinforcing its strategy to hedge against currency fluctuations and improve shareholder value. 
Via Stocktwits
News headline image
These stocks are moving in today's pre-market session ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
From Quantum BioPharma
Via GlobeNewswire
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Dosing in Key Toxicity Studies for MS Drug Candidate
Via Investor Brand Network
News headline image
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.